Showing results (111-120 of 379) with videos related to

Sort By:
Pageof 38
Plos Medicine|August 29, 2012
Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: a systematic review and meta-analysisJicheng Lv, Bruce Neal, Parya Ehteshami, et al.
Plos Medicine|October 24, 2008
The relationship between proteinuria and coronary risk: a systematic review and meta-analysisVlado Perkovic, Christine Verdon, Toshiharu Ninomiya, et al.
BMJ (Clinical Research Ed.)|June 15, 2012
The effect of folic acid based homocysteine lowering on cardiovascular events in people with kidney disease: systematic review and meta-analysisMeg J Jardine, Amy Kang, Sophia Zoungas, et al.
Kidney International|May 30, 2020
Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetesJingWei Li, Bruce Neal, Vlado Perkovic, et al.
BMJ (Clinical Research Ed.)|February 4, 2015
The association between kidney function and major bleeding in older adults with atrial fibrillation starting warfarin treatment: population based observational studyMin Jun, Matthew T James, Braden J Manns, et al.
Heart, Lung & Circulation|November 6, 2022
Oral Anticoagulant Use in Patients With Atrial Fibrillation and Chronic Kidney Disease: A Review of the Evidence With Recommendations for Australian Clinical PracticeChristopher Hammett, Sunil V Badve, Peter G Kerr, et al.
Endocrinology, Diabetes & Metabolism|July 19, 2021
Canagliflozin, serum magnesium and cardiovascular outcomes-Analysis from the CANVAS ProgramKatherine M Wang, JingWei Li, Vivek Bhalla, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 12, 2021
Rationale, design, demographics and baseline characteristics of the randomized, controlled, Phase 2b SAPPHIRE study of verinurad plus allopurinol in patients with chronic kidney disease and hyperuricaemiaHiddo J L Heerspink, Austin G Stack, Robert Terkeltaub, et al.
Cardiovascular Diabetology|September 23, 2022
Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failureSok Cin Tye, Niels Jongs, Steven G Coca, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|June 8, 2025
Systemic Inflammation and the Risks of Adverse Kidney Outcomes in Adults With Atherosclerotic Cardiovascular DiseaseFaizan Mazhar, Edouard L Fu, Anne-Laure Faucon, et al.
Pageof 38